secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001558370-23-017980
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium Q3 revenue $136.7M (+8% YoY), adj. EBITDA record $89.4M, guidance tightened
--------------------------------------------------------------------------------

- GAAP net income $20.6M vs $0.5M; diluted EPS $0.53; adjusted EPS $1.34.
- Belbuca net revenue $45.4M (+17% YoY); Xtampza ER $39.8M; Nucynta franchise $47.5M.
- Updated FY23 guidance: revenue $565-570M, adj. EBITDA $360-365M, op. expenses $125-130M.
- Nucynta exclusivity extended to July 2026; board authorized $25M ASR program.
- Cash and securities $304.6M, up from $173.7M at Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000155837023017980/0001558370-23-017980-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000155837023017980/coll-20231107x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-017980

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer